PL2691533T3 - Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki - Google Patents
Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na lekiInfo
- Publication number
- PL2691533T3 PL2691533T3 PL12710755T PL12710755T PL2691533T3 PL 2691533 T3 PL2691533 T3 PL 2691533T3 PL 12710755 T PL12710755 T PL 12710755T PL 12710755 T PL12710755 T PL 12710755T PL 2691533 T3 PL2691533 T3 PL 2691533T3
- Authority
- PL
- Poland
- Prior art keywords
- akt
- phospho
- biomarker
- drug response
- drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160275 | 2011-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2691533T3 true PL2691533T3 (pl) | 2017-09-29 |
Family
ID=44316937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12710755T PL2691533T3 (pl) | 2011-03-29 | 2012-03-28 | Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10006078B2 (pl) |
| EP (1) | EP2691533B1 (pl) |
| JP (1) | JP6334393B2 (pl) |
| CN (1) | CN103502467B (pl) |
| AU (1) | AU2012234297B2 (pl) |
| CA (1) | CA2828381A1 (pl) |
| DK (1) | DK2691533T3 (pl) |
| ES (1) | ES2627972T3 (pl) |
| HU (1) | HUE032315T2 (pl) |
| PL (1) | PL2691533T3 (pl) |
| PT (1) | PT2691533T (pl) |
| WO (1) | WO2012130887A1 (pl) |
| ZA (1) | ZA201306520B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2691533T (pt) * | 2011-03-29 | 2017-06-20 | Basilea Pharmaceutica Ag | Utilização de fosfo-akt como um biomarcador da resposta farmacológica |
| JP7034072B2 (ja) * | 2015-10-22 | 2022-03-11 | バジリア・ファルマスーチカ・インターナショナル・アーゲー | 薬物応答のバイオマーカーとしてのｅｂ１の使用 |
| CN108404130B (zh) * | 2017-02-10 | 2021-02-02 | 上海市第一人民医院 | DMAP1 pY246阻断剂在制备抗肿瘤药物中的应用 |
| KR102648947B1 (ko) * | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
| EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| CN107158388B (zh) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | MIIP pS303阻断剂在制备抗肿瘤药物中的应用 |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1636215B1 (en) * | 2003-05-23 | 2008-01-23 | Basilea Pharmaceutica AG | Furazanobenzimidazoles |
| JP2012527631A (ja) * | 2009-05-22 | 2012-11-08 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ | タキサン型化学療法剤用のインジケータとしてのｓｅｒ４７３でのａｋｔリン酸化反応 |
| WO2011012577A1 (en) * | 2009-07-27 | 2011-02-03 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
| HUE032625T2 (en) * | 2011-01-21 | 2017-10-30 | Basilea Pharmaceutica Ag | Use of Stathmin as a biomarker for the drug response to furazanobenzimidazoles |
| JP6302673B2 (ja) * | 2011-01-21 | 2018-03-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 |
| PT2666014T (pt) * | 2011-01-21 | 2016-12-22 | Basilea Pharmaceutica Ag | Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
| PL2678679T3 (pl) * | 2011-02-24 | 2017-07-31 | Basilea Pharmaceutica Ag | Zastosowanie acetylowanej tubuliny jako biomarkera odpowiedzi lekowej na furazanobenzoimidazole |
| PT2691533T (pt) * | 2011-03-29 | 2017-06-20 | Basilea Pharmaceutica Ag | Utilização de fosfo-akt como um biomarcador da resposta farmacológica |
-
2012
- 2012-03-28 PT PT127107555T patent/PT2691533T/pt unknown
- 2012-03-28 EP EP12710755.5A patent/EP2691533B1/en active Active
- 2012-03-28 JP JP2014501598A patent/JP6334393B2/ja not_active Expired - Fee Related
- 2012-03-28 WO PCT/EP2012/055522 patent/WO2012130887A1/en active Application Filing
- 2012-03-28 CN CN201280015386.2A patent/CN103502467B/zh not_active Expired - Fee Related
- 2012-03-28 PL PL12710755T patent/PL2691533T3/pl unknown
- 2012-03-28 HU HUE12710755A patent/HUE032315T2/en unknown
- 2012-03-28 US US14/005,680 patent/US10006078B2/en not_active Expired - Fee Related
- 2012-03-28 ES ES12710755.5T patent/ES2627972T3/es active Active
- 2012-03-28 CA CA2828381A patent/CA2828381A1/en not_active Abandoned
- 2012-03-28 DK DK12710755.5T patent/DK2691533T3/en active
- 2012-03-28 AU AU2012234297A patent/AU2012234297B2/en not_active Ceased
-
2013
- 2013-08-29 ZA ZA2013/06520A patent/ZA201306520B/en unknown
-
2018
- 2018-05-30 US US15/992,813 patent/US10724072B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ614718A (en) | 2015-07-31 |
| US10724072B2 (en) | 2020-07-28 |
| WO2012130887A1 (en) | 2012-10-04 |
| JP6334393B2 (ja) | 2018-05-30 |
| AU2012234297B2 (en) | 2016-03-03 |
| HUE032315T2 (en) | 2017-09-28 |
| US20190010536A1 (en) | 2019-01-10 |
| US10006078B2 (en) | 2018-06-26 |
| JP2014512001A (ja) | 2014-05-19 |
| DK2691533T3 (en) | 2017-07-10 |
| EP2691533A1 (en) | 2014-02-05 |
| CA2828381A1 (en) | 2012-10-04 |
| EP2691533B1 (en) | 2017-04-05 |
| PT2691533T (pt) | 2017-06-20 |
| ES2627972T3 (es) | 2017-08-01 |
| CN103502467B (zh) | 2016-08-17 |
| ZA201306520B (en) | 2014-11-26 |
| US20140080872A1 (en) | 2014-03-20 |
| CN103502467A (zh) | 2014-01-08 |
| AU2012234297A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| IL229254A0 (en) | Therapeutic antibodies | |
| GB201118773D0 (en) | Probe | |
| ZA201306520B (en) | Use of phospho-akt as a biomarker of drug response | |
| EP2712534A4 (en) | PROBE | |
| HK1192323A1 (zh) | -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
| GB201116131D0 (en) | Probe | |
| GB2494153B (en) | Selection of codecs | |
| HK1185947A1 (zh) | 作為呋咱並苯並咪唑類藥物應答的生物標記的用途 | |
| EP2654196A4 (en) | TRANSDUCER | |
| HK1199040A1 (en) | Use of antibody | |
| ZA201402437B (en) | Diagnosis of tuberculosis | |
| GB201117172D0 (en) | Diabetes | |
| GB2488327B (en) | Structure of brewing device | |
| EP2783690A4 (en) | NEW USE OF NEOHESPERIDINE | |
| EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
| GB201110637D0 (en) | Fold-up displays | |
| ZA201308992B (en) | Therapeutic antibodies | |
| GB201121280D0 (en) | Biomarker | |
| GB201107838D0 (en) | Biomarker |